Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Advances in Diabetic Retinopathy, Diabetic Cataract, and Other Diabetic...
share announcement

Clinical Advances in Diabetic Retinopathy, Diabetic Cataract, and Other Diabetic Eye Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".

Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 6678

Special Issue Editor

Prof. Dr. Teruyo Kida

E-Mail
Guest Editor
Department of Ophthalmology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan
Interests: diabetic retinopathy; retinal vein occlusion; diabetic macular edema; VEGF; aquaporin; retinal venous pressure

Special Issue Information

Dear Colleagues,

With age-associated frailty of the eye, diabetes sometimes deteriorates the quality of vision and leads to risk of blindness. Diabetes also causes various eye complications, including the following: cataracts; retinopathy; macular edema; retinal vascular diseases, such as retinal vein occlusion, atherosclerosis, and ocular ischemic syndrome, following internal carotid artery stenosis; and neovascular glaucoma. Imaging technology (wide-field fundus camera, optical coherence tomography (OCT), and OCT angiography, etc.) has progressed rapidly and treatments for diabetic eye disease (laser therapy, vitrectomy, eye injection with anti-VEGF drug or steroid, and systemic drugs for hyperglycemia) have been developed. However, there is still a need to focus on potential new therapies, minimally invasive treatments, more sustainable methods of treatment than traditional therapy, etc., to prevent diabetic eye disease.

This Special Issue aims to provide updated information including original clinical and laboratory research regarding the diagnosis and treatment of diabetic eye disease. Researchers in this field are encouraged to submit an original article or review to this Special Issue (case reports are not accepted).

Prof. Dr. Teruyo Kida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • complication
  • cataract
  • diabetic retinopathy
  • diabetic macular edema
  • ocular ischemic syndrome
  • neovascular glaucoma
  • OCT
  • imaging
  • treatment

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1510 KiB  
Article
Retinal Microvascular Changes after Intravitreal Triamcinolone Acetonide in Diabetic Macular Edema
by Fusae Kato, Miho Nozaki, Aki Kato and Tsutomu Yasukawa
J. Clin. Med. 2023, 12(10), 3475; https://doi.org/10.3390/jcm12103475 - 15 May 2023
Cited by 4 | Viewed by 1172
Abstract
Intravitreal injection of triamcinolone acetonide (TA) is essential for clinical treatment in patients who insufficiently respond to vascular endothelial factor inhibitors for diabetic macular edema (DME). The aim of this study was to investigate microvascular changes treated with TA using optical coherence tomography [...] Read more.
Intravitreal injection of triamcinolone acetonide (TA) is essential for clinical treatment in patients who insufficiently respond to vascular endothelial factor inhibitors for diabetic macular edema (DME). The aim of this study was to investigate microvascular changes treated with TA using optical coherence tomography angiography (OCTA). After TA in twelve eyes of eleven patients with central retinal thickness (CRT), there was a 20% or more reduction observed. Visual acuity, the number of microaneurysms, vessel density, and the foveal avascular zone (FAZ) area were compared before and at 2 months after TA. At baseline, the number of microaneurysms was 2.1 ± 1.1 in the superficial capillary plexuses (SCP) and 2.0 ± 1.1 in the deep capillary plexuses (DCP), with a significant decrease post-treatment to 1.0 ± 1.0 for SCP and 0.8 ± 0.8 for DCP (SCP; p = 0.018, DCP; p = 0.008). There was significant enlargement of the FAZ area from 0.28 ± 0.11 mm2 to 0.32 ± 0.14 mm2 (p = 0.041). There was no significant difference in the visual acuity and vessel density of SCP and DCP. Results indicated that OCTA was useful for the evaluation of qualitative and morphological retinal microcirculation and that intravitreal TA may decrease microaneurysms. Full article
(This article belongs to the Special Issue Clinical Advances in Diabetic Retinopathy, Diabetic Cataract, and Other Diabetic Eye Disease)
►▼ Show Figures

Figure 1

11 pages, 1743 KiB  
Article
Glycemic Control after Initiation of Anti-VEGF Treatment for Diabetic Macular Edema
by Hideyuki Oshima, Yoshihiro Takamura, Takao Hirano, Masahiko Shimura, Masahiko Sugimoto, Teruyo Kida, Takehiro Matsumura, Makoto Gozawa, Yutaka Yamada, Masakazu Morioka and Masaru Inatani
J. Clin. Med. 2022, 11(16), 4659; https://doi.org/10.3390/jcm11164659 - 9 Aug 2022
Cited by 3 | Viewed by 1895
Abstract
Diabetic macular edema (DME) induces visual disturbance, and intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs are the accepted first-line treatment. We investigate its impact on glycemic control after starting VEGF treatment for DME on the basis of a questionnaire and changes [...] Read more.
Diabetic macular edema (DME) induces visual disturbance, and intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs are the accepted first-line treatment. We investigate its impact on glycemic control after starting VEGF treatment for DME on the basis of a questionnaire and changes in hemoglobin A1c (HbA1c). We conducted a retrospective multicenter study analyzing 112 patients with DME who underwent anti-VEGF therapy and their changes in HbA1c over two years. Central retinal thickness and visual acuity significantly improved at three months and throughout the period after initiating therapy (p < 0.0001); a significant change in HbA1c was not found. A total of 59.8% of patients became more active in glycemic control through exercise and diet therapy after initiating therapy, resulting in a significantly lower HbA1c at 6 (p = 0.0047), 12 (p = 0.0003), and 18 (p = 0.0117) months compared to patients who did not. HbA1c was significantly lower after 18 months in patients who stated that anti-VEGF drugs were expensive (p = 0.0354). The initiation of anti-VEGF therapy for DME affects HbA1c levels in relation to more aggressive glycemic control. Full article
(This article belongs to the Special Issue Clinical Advances in Diabetic Retinopathy, Diabetic Cataract, and Other Diabetic Eye Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 322 KiB  
Review
Examining the Role of Telemedicine in Diabetic Retinopathy
by Matthew R. Land, Parth A. Patel, Tommy Bui, Cheng Jiao, Arsalan Ali, Shadman Ibnamasud, Prem N. Patel and Veeral Sheth
J. Clin. Med. 2023, 12(10), 3537; https://doi.org/10.3390/jcm12103537 - 18 May 2023
Cited by 1 | Viewed by 2776
Abstract
With the increasing prevalence of diabetic retinopathy (DR), screening is of the utmost importance to prevent vision loss for patients and reduce financial costs for the healthcare system. Unfortunately, it appears that the capacity of optometrists and ophthalmologists to adequately perform in-person screenings [...] Read more.
With the increasing prevalence of diabetic retinopathy (DR), screening is of the utmost importance to prevent vision loss for patients and reduce financial costs for the healthcare system. Unfortunately, it appears that the capacity of optometrists and ophthalmologists to adequately perform in-person screenings of DR will be insufficient within the coming years. Telemedicine offers the opportunity to expand access to screening while reducing the economic and temporal burden associated with current in-person protocols. The present literature review summarizes the latest developments in telemedicine for DR screening, considerations for stakeholders, barriers to implementation, and future directions in this area. As the role of telemedicine in DR screening continues to expand, further work will be necessary to continually optimize practices and improve long-term patient outcomes. Full article
(This article belongs to the Special Issue Clinical Advances in Diabetic Retinopathy, Diabetic Cataract, and Other Diabetic Eye Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop